<DOC>
	<DOCNO>NCT01544595</DOCNO>
	<brief_summary>This extension study secukinumab prefilled syrinx subject moderate severe chronic plaque-type psoriasis complete precede psoriasis phase III study secukinumab . Subjects secukinumab end treatment period phase III study ( e.g. , ongoing CAIN457A2302 CAIN457A2303 potentially secukinumab phase III study ) eligible join extension study . This extension study plan collect additional 2 year long-term efficacy , safety , tolerability data secukinumab either continuous interrupted therapy ( randomize withdrawal period ) subject show least partial response secukinumab complete treatment period secukinumab previous phase III study . In extension study , prefilled syringe ( PFS ) liquid formulation secukinumab use .</brief_summary>
	<brief_title>Extension Study Secukinumab Prefilled Syringes Subjects With Moderate Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Completed full study treatment period 52 week precede phase III study , receive secukinumab treatment maintenance phase precede phase III study , show least partial response ( PASI 50 better ) Week 52 precede phase III study . Written inform consent form . Exclusion criterion : A protocol deviation either precede phase III study accord investigator prevent meaningful analysis extension study individual subject . Ongoing use prohibit psoriasis nonpsoriasis treatment . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test ( &gt; 10 mIU/mL ) . Women childbearing potential , defined woman physiologically capable become pregnant , unwilling use effective contraception study 16 week stop treatment . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Psoriasis , inflammatory skin disease</keyword>
	<keyword>scaly patch</keyword>
	<keyword>secukinumab ( AIN457 )</keyword>
	<keyword>Psoriasis Area Severity Index ( PASI )</keyword>
	<keyword>Investigator Global Assessment ( IGA ) mod 2011</keyword>
</DOC>